Phase 1/2 Trial Pauses Enrollment for Evaluation of MGTA-117 in AML/MDS After Patient Death

Article

Magenta Therapeutics has voluntarily paused enrollment for a phase 1/2 trial evaluating the antibody-drug conjugate MGTA-117 in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome following the death of a patient.

Magenta Therapeutics has voluntarily paused enrollment for a phase 1/2 trial (NCT05223699) evaluating the antibody-drug conjugate (ADC) MGTA-117 in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) following the death of a patient.1

The patient assigned to an MGTA-117 dose of 0.08 mg/kg experienced a grade 5 serious adverse effect (AE) of respiratory failure and cardiac arrest, which was deemed to be possibly related to MGTA-117. The company said it has reported known information to the FDA as a suspected unexpected serious adverse reaction.

The trial was paused following a consultation with the trial’s safety cohort review committee. Magenta Therapeutics is currently evaluating available data and determining the next steps for the development of MGTA-117.

MGTA-117 is a novel ADC targeting CD117 in development as a single agent for myeloid conditioning prior to hematopoietic stem cell transplantation (HSCT).2

The phase 1/2 trial was enrolling patients with relapsed/refractory AML who experienced primary induction failure or patients with myelodysplasia–excess blasts (MDS-EB) who failed or were refractory to a hypomethylating agent.3 Patients were also required to have CD117-positive disease per immunohistochemistry or flow cytometry; have an identified HSC donor, haplo-identical transplant donor, or umbilical blood donor; have an ECOG performance status of 2 or less; and have adequate hepatic and cardiac function.

Key exclusion criteria included acute promyelocytic leukemia, known active central nervous system leukemia or chloroma, HSCT within 6 months prior to dosing, CAR T-cell therapies within 6 months prior to dosing, or active graft-vs-host disease.

The study used standard 3+3 design to evaluate 5 different doses of MGTA-117 across 5 single-dose cohorts of 0.02 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.13 mg/kg, and 0.19 mg/kg. The primary objectives of the trial were to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential anti-leukemia activity of MGTA-117, as well as to establish the minimum safe and biologically effective single dose of MGTA-117.

Previously reported findings presented at the 2022 ASH Annual Meeting from the first 15 patients treated during the study showed that MGTA-117 was well tolerated, with no unexpected or serious treatment-related AEs or dose-limiting toxicities.2 Regarding pharmacokinetics, MGTA-117 was found to rapidly clear from the blood, and the ADC was found to bind to CD117-positive cells in the blood of all patients. MGTA-117 was found to deplete target cells in both the blood and bone marrow.

References

  1. Magenta Therapeutics voluntarily pauses the MGTA-117 phase 1/2 dose-escalation clinical trial to investigate drug safety. News release. Magenta Therapeutics. January 25, 2023. Accessed January 26, 2023. http://bit.ly/3H7WMoN
  2. Westervelt P, Kebriaei P, Juckett M, et al. MGTA-117, an anti-CD117 antibody-drug conjugated with amanitin, in participants with relapsed/refractory adult acute myeloid leukemia (AML) and myelodysplasia with excess blasts (MDS-EB): safety, pharmacokinetics and pharmacodynamics initial findings from a phase 1/2 study. Blood. 2022;140(Suppl 1):2117–2119. doi:10.1182/blood-2022-162406
  3. Study of MGTA-117 in patients with adult acute myeloid leukemia (AML) and myelodysplasia-excess blasts (MDS-EB). ClinicalTrials.gov. Updated November 25, 2022. Accessed January 26, 2023. https://clinicaltrials.gov/ct2/show/NCT05223699

Related Videos
Naseema Gangat, MBBS
Ashwin Kishtagari, MD
Somedeb Ball, MBBS
Rebecca Klisovic, MD
Sunil Iyer, MD
Sunil Iyer, MD
Akriti Jain, MD
Joseph G. Jurcic, MD
Akriti Jain, MD
Akriti Jain, MD